PMID- 27344079
OWN - NLM
STAT- MEDLINE
DCOM- 20171204
LR  - 20220409
IS  - 1778-7254 (Electronic)
IS  - 1297-319X (Linking)
VI  - 84
IP  - 2
DP  - 2017 Mar
TI  - Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: 
      A prospective multicentre study.
PG  - 169-173
LID - S1297-319X(16)30096-3 [pii]
LID - 10.1016/j.jbspin.2016.03.014 [doi]
AB  - OBJECTIVE: As many inflammatory rheumatic diseases affect patients in 
      childbearing age, some concern has been expressed about the safety of biologic 
      drugs during pregnancy. This study evaluated the effects of anti-tumor necrosis 
      factor alpha (TNFalpha) agents on pregnancy/foetal outcomes. METHODS: Thirty-eight 
      pregnancies were followed prospectively from November 2008 to February 2015. 
      Information about the patients' exposure to anti-TNFalpha, disease activity, DMARD 
      therapy, pregnancy/foetal outcomes were registered. RESULTS: Twenty-four/38 
      (71.1%) pregnancies were exposed to anti-TNFalpha at conception/I trimester, 11/38 
      (28.9%) prior to conception and 3 (11.1%) following paternal exposure. There were 
      two congenital malformations: one infant (4.2%) was diagnosed with congenital 
      diaphragmatic hernia and obstructive megaureter; the mother was exposed to 
      adalimumab at conception/I trimester. While one foetus (9.1%) showed a trisomy 
      16, the mother 38 year-old had suspended etanercept 4 weeks before conception. 
      There was no significant difference in pregnancy/foetal outcome between the two 
      groups. Nor were there any significant differences in pregnancy/foetal outcomes 
      in the various groups being treated with different anti-TNFalpha antagonists. No 
      congenital malformations were found in connection to paternal exposure. 
      CONCLUSION: Study results suggest that anti-TNFalpha drugs could be safe when 
      administered during conception/I trimester and following paternal exposure.
CI  - Copyright (c) 2016 Societe francaise de rhumatologie. Published by Elsevier SAS. 
      All rights reserved.
FAU - Hoxha, Ariela
AU  - Hoxha A
AD  - Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 
      2, 35128 Padova, Italy. Electronic address: arielahoxha@hotmail.com.
FAU - Calligaro, Antonia
AU  - Calligaro A
AD  - Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 
      2, 35128 Padova, Italy.
FAU - Di Poi, Emma
AU  - Di Poi E
AD  - Clinic of Rheumatology, DSMB, University Hospital "Santa Maria della 
      Misericordia", 33100 Udine, Italy.
FAU - Peccatori, Susanna
AU  - Peccatori S
AD  - Rheumatology Unit, S. Chiara Hospital, 38122 Trento, Italy.
FAU - Favaro, Maria
AU  - Favaro M
AD  - Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 
      2, 35128 Padova, Italy.
FAU - Del Ross, Teresa
AU  - Del Ross T
AD  - Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 
      2, 35128 Padova, Italy.
FAU - Ramonda, Roberta
AU  - Ramonda R
AD  - Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 
      2, 35128 Padova, Italy.
FAU - Grava, Chiara
AU  - Grava C
AD  - Department of Medicine, S. Martino Hospital, 32100 Belluno, Italy.
FAU - Raffeiner, Bernd
AU  - Raffeiner B
AD  - Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 
      2, 35128 Padova, Italy.
FAU - Ravagni, Paola
AU  - Ravagni P
AD  - Rheumatology Unit, S. Chiara Hospital, 38122 Trento, Italy.
FAU - De Vita, Salvatore
AU  - De Vita S
AD  - Clinic of Rheumatology, DSMB, University Hospital "Santa Maria della 
      Misericordia", 33100 Udine, Italy.
FAU - Ruffatti, Amelia
AU  - Ruffatti A
AD  - Rheumatology Unit, Department of Medicine, University of Padua, Via Giustiniani, 
      2, 35128 Padova, Italy.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
DEP - 20160622
PL  - France
TA  - Joint Bone Spine
JT  - Joint bone spine
JID - 100938016
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adult
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Rheumatoid/*drug therapy
MH  - Female
MH  - Fetal Diseases/chemically induced
MH  - Humans
MH  - Middle Aged
MH  - Pregnancy
MH  - Pregnancy Outcome
MH  - Prospective Studies
MH  - Spondylarthropathies/*drug therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
OTO - NOTNLM
OT  - Ankylosing spondylitis
OT  - Anti-TNFalpha agents
OT  - Foetal outcome
OT  - Pregnancy
OT  - Psoriatic arthritis
OT  - Rheumatoid arthritis
EDAT- 2016/06/28 06:00
MHDA- 2017/12/05 06:00
CRDT- 2016/06/27 06:00
PHST- 2015/11/10 00:00 [received]
PHST- 2016/03/24 00:00 [accepted]
PHST- 2016/06/28 06:00 [pubmed]
PHST- 2017/12/05 06:00 [medline]
PHST- 2016/06/27 06:00 [entrez]
AID - S1297-319X(16)30096-3 [pii]
AID - 10.1016/j.jbspin.2016.03.014 [doi]
PST - ppublish
SO  - Joint Bone Spine. 2017 Mar;84(2):169-173. doi: 10.1016/j.jbspin.2016.03.014. Epub 
      2016 Jun 22.